Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0088 • ACR Convergence 2025
Imbalance of Inflammation-Regulating Microorganisms and Predicted Metabolomic Pathways Associates With Disease Evolution in Individuals At-Risk for Rheumatoid Arthritis
Lyndsey Cole¹, Brendan Allen², Sucai Liu², Marie Feser³, Le Yi Phyo², LauraKay Moss², Daniel Frank², J. Kirk Harris², Kristen Demoruelle⁴, Kevin Deane⁵, V. Michael Holers⁶ and Kristine Kuhn⁷, ¹University of Colorado School of Medicine, Centennial, CO, ²University of Colorado School of Medicine, Aurora, CO, ³University of Colorado Anschutz Medical Campus, Aurora, CO, ⁴University of Colorado Anschutz Medical Campus, Golden, CO, ⁵University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁶University of Colorado Anschutz Medical Campus, Aurora, ⁷²⁰²² - ²⁰²³ / Adult/ University of Colorado, Aurora, CO
Background/Purpose: The mucosal origins hypothesis of RA proposes that immune responses to microorganisms at mucosal sites (e.g. intestine) lead to systemic inflammation and autoimmunity. Little…
Abstract Number: 0068 • ACR Convergence 2025
Unique Fibroblast-like Synoviocyte Phenotype with Elevated MCSF Expression Induced by TLR5 Activation in Rheumatoid Arthritis
Aryan Patel¹, Osama Al Zoubi² and Shiva Shahrara³, ¹University of Illinois at Chicago, Chicago, ²University of Illinois at Chicago, Chicago, IL, ³University of Illinois, Chicago, IL
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting approximately 1% of the global population, causing significant morbidity and disability. Fibroblast-like synoviocytes (FLS) are…
Abstract Number: 0035 • ACR Convergence 2025
Clinical and Transcriptomic Heterogeneity in Patients With RA: A Multi-Centric International Study of Anti-TNF Response
Maryna Borshchivska¹, Thibault Helleputte¹, Laurent Meric de Bellefon², Silvana di Romana³, Elsa Vieira-Sousa⁴, Vasco Romão⁴, João Eurico Fonseca⁵, Alla Ishchenko⁶, Patrick Verschueren⁶, Ruth Wittoek⁷, Peggy jacques⁷, Dirk Elewaut⁸, Bernard Lauwerys⁹ and Patrick Durez¹⁰, ¹DNAlytics, Louvain-la-Neuve, Belgium, ²Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatologie, Brussels, Belgium, ³Department of Rheumatology, Saint Pierre University Hospital, Brussels, Belgium, ⁴Faculdade Medicina, Universidade de Lisboa, ULS Santa Maria, Centro Académico Medicina de Lisboa, Lisboa, Portugal, ⁵Faculdade Medicina, Universidade de Lisboa, ULS Santa Maria, Centro Académico Medicina de Lisboa, Lisboa, Lisboa, Portugal, ⁶Rheumatology, University Hospital Leuven and Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium, ⁷VIB Center for Inflammation Research, Ghent University and Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁸VIB Center for Inflammation Research, and Ghent University Hospital, Department of Rheumatology, Ghent, Belgium, ⁹Systemic and Inflammatory Rheumatic Diseases Section, Institute of Experimental and Clinical Research (IREC), UCLouvain, Brussels, Belgium, ¹⁰Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatologie, Brussels, Brussels Hoofdstedelijk Gewest, Belgium

Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that can lead to joint damage and disability. Although methotrexate is the standard first-line treatment, about…
Abstract Number: 2642 • ACR Convergence 2025
Impact of Rheumatoid Arthritis Therapeutic Classes on Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism: A Population-Based Cohort Study
Mohammad Movahedi¹, Angela Cesta¹, Sibel Aydin², Pooneh Akhavan³, Tetyana Kendzerska⁴, Claire Bombardier¹ and Bindee Kuriya⁵, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, ON, Canada, ³self-employed, Toronto, ON, Canada, ⁴Ottawa Hospital Research Institute, Mississuaga, ON, Canada, ⁵University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of major adverse cardiovascular events (MACE) and venous thromboembolism (VTE). Inflammation is a driver of…
Abstract Number: 2397 • ACR Convergence 2025
Analytical Performance of a Fully Automated Multiplexed Microarray Immunoassay for the Simultaneous Detection of Fifteen Autoantibodies Associated with Connective Tissue Diseases in a Reference Laboratory in Southern France
Guillaume Nardella¹, Gerber Gomez², Christian Fischer² and Claire Monat¹, ¹Inovie Labosud Provence, Specialized Autoimmunity Analyses, Marseille, France, ²Scientific & Medical Affairs, AliveDx Suisse SA, Eysins, Switzerland
Background/Purpose: Autoantibodies are key diagnostic markers in autoimmune connective tissue diseases (CTD). Conventional testing often requires multiple single-measurand assays, which can be labor-intensive and time-consuming.…
Abstract Number: 2274 • ACR Convergence 2025
Importance Of Fc Region On Therapeutic Survival In Rheumatoid Arthritis Patients With Anti-TNF Therapy
ELENA GRAU GARCIA¹, Iago Alcántara Álvarez², Jose Ivorra Cortes³, Pablo Muñoz Martinez⁴, Laura Mas Sanchez⁵, Alba Maria Torrat Noves⁶, Daniel Ramos Castro⁷, Belen Villanueva Manes⁸, Miguel Simeo Vinaixa⁴, Andres Perez Hurtado⁹ and José Andrés Román Ivorra¹⁰, ¹HUP La Fe, Valencia, Comunidad Valenciana, Spain, ²Hospital Universitari i Politénic La Fe, València, Spain, ³Hospital Universitario La Fe, Valencia, Comunidad Valenciana, Spain, ⁴Rheumatology Department. HUP La Fe, Valencia, Spain, ⁵Hospital Universitari i Politecnic La Fe, València, Spain, ⁶Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Spain, ⁷Hospital Universitari i Politecnic La Fe, Valencia, Spain, ⁸Hospital La Fe, València, Spain, ⁹Hospital Universitario y Politècnico La Fe, València, Comunidad Valenciana, Spain, ¹⁰Hospital Universitari i Politècnic La Fe, Valencia, Spain
Background/Purpose: In patients affected by rheumatoid arthritis (RA), it has been studied a relation between high rheumatoid factor (RF) and a favorable response to anti-TNF…
Abstract Number: 2259 • ACR Convergence 2025
Lung Transplant Outcomes in Patients with Rheumatoid Arthritis Associated Interstitial Lung Disease Compared to Idiopathic Pulmonary Fibrosis: A Multicentric Retrospective Analysis and Meta-analysis
Saud AlHajeri¹, Matthew Major², Darya S. Jalaledin³, Beatrice Daviault⁴, Arusa Shah⁵, Alec Yu⁶, Sabrina Hoa⁷, Robert Levy⁸, Jennifer Wilson¹, Charles Poirier⁴, James Choi⁶, John Yee⁶, Océane Landon-Cardinal⁹, Kun Huang¹⁰ and Hyein Kim¹¹, ¹UBC, Vancouver, BC, Canada, ²University of British Columbia, Vancouver, Canada, ³Université de Montréal, Saint-Lambert, QC, Canada, ⁴University of Montreal, Montreal, QC, Canada, ⁵University of Montreal, Montreal, BC, Canada, ⁶University of British Columbia, Vancouver, BC, Canada, ⁷University of Montreal, Brossard, QC, Canada, ⁸University of British Columbia, Deerfield, IL, ⁹Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ¹⁰University of British Columbia, Vancouver, Surrey, BC, Canada, ¹¹The University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Interstitial lung disease (ILD) is a frequent complication of rheumatoid arthritis (RA), ranging from subclinical ILD to advanced fibrosis, and is associated with significant…
Abstract Number: 2243 • ACR Convergence 2025
Differences In GDF-15 Levels In Rheumatoid Arthritis Patients With Remission Or Mild Disease Activity Are Associated With Fewer Depressive Symptoms: Clinical Data And Bioinformatic Analysis
Jessica Roldan Ortega¹, Mario Peña², Evelyn Aranda Cano³, Luz Viruel⁴, Itzel Palafox Sosa⁵, David Vera Bustamante⁶, Fausto Sanchez-Muñoz², Yaneli Juarez-Vicuña⁷ and Laura Aline Martinez-Martinez⁸, ¹INSTITUTO NACIONAL DE CARDIOLOGIA, Ciudad de México, Federal District, Mexico, ²Instituto Nacional de Cardiologia Ignacio Chavez, Mexico city, Mexico, ³Departament of rheumatology Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de Mexico, Federal District, Mexico, ⁴Universidad Autónoma del Estado de Hidalgo, Tula de Allende, Hidalgo, Mexico, ⁵Escuela Superior de Medicina-Instituto Politècnico Nacional, ciudad de mexico, Federal District, Mexico, ⁶Benemérita Universidad Autónoma de Puebla, Heroica Puebla de Zaragoza, Puebla, Mexico, ⁷Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico City, Mexico, ⁸Rheumatology Department at National Institute of Cardiology Ignacio Chávez, Mexico City, Federal District, Mexico
Background/Purpose: Depression is a common comorbidity in rheumatoid arthritis patients and has a significant effect on the disease course. [Brock J, et al. Nat Rev…
Abstract Number: 2220 • ACR Convergence 2025
Human Milk Fatty Acid Profiles Among Breastfeeding Mothers With and Without Systemic Autoimmune Rheumatic Diseases
Rashmi Dhital¹, Kerri Bertrand², Dilli Poudel³, Christina Chambers⁴ and Monica Guma², ¹Vanderbilt University Medical Center, Brentwood, TN, ²University of California San Diego, San Diego, CA, ³Vanderbilt University Medical Center, Nashville, TN, ⁴University of California, San Diego, La Jolla, CA
Background/Purpose: Systemic autoimmune rheumatic diseases (SARDs) such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are characterized by chronic systemic inflammation and often require…
Abstract Number: 1955 • ACR Convergence 2025
Regional variations in the relationship between pericoronary fat enhancement and atherosclerosis may reflect differences in local vascular inflammation in rheumatoid arthritis
George Karpouzas¹, Frederik Enevoldsen², Dzenan Masic², Matthew Budoff¹, Ellen-Margrethe Hauge² and Sarah Ormseth³, ¹Harbor-UCLA Medical Center, Torrance, CA, ²Aarhus University, Aarhus, Denmark, ³The Lundquist Institute for Biomedical Innovation, Torrance, CA
Background/Purpose: The composition of fat around the coronary arteries is evaluated as pericoronary adipose tissue attenuation (PCATa) on coronary CT-angiogram (CCTA). In general patients PCATa…
Abstract Number: 1886 • ACR Convergence 2025
Thirty Percent of Older Adults with Rheumatic Disease Receive High-Risk Medication
Christine Anastasiou¹, Eric Roberts², gabriela Schmajuk³ and Jinoos Yazdany⁴, ¹Stanford University, Pleasanton, CA, ²University of California, San Francisco, SF, CA, ³University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ⁴UCSF, San Francisco, CA
Background/Purpose: High-risk medications (HRMs) may increase the risk of adverse events such as falls and fractures, hospitalizations, hospital length of stay, and death in older…
Abstract Number: 1703 • ACR Convergence 2025
Predicting Rheumatoid Arthritis Flare Using Longitudinal Cytokine Trajectories, Machine Learning and Spatial Transcriptomic Imaging
Wittaya Suwakulsiri¹, Lukas Andriessen², Coline Fournier³, Saritha Kodikara⁴, Amy Anderson⁵, Jasmine Sim⁵, Kim-Anh Le Cao⁴, Yann Abraham⁶, Kevin Wei⁷, Kenneth Baker⁵, Arthur Pratt⁸, Mihir Wechalekar⁹, John Isaacs¹⁰ and Ranjeny Thomas¹, ¹Frazer Institute, University of Queensland, Brisbane, Queensland, Australia, ²Frazer Institute, University of Queensland, Woolloongabba, Queensland, Australia, ³Melbourne Integrative Genomics & School of Mathematics and Statistics, The University of Melbourne, Melbourne, Australia, ⁴Melbourne Integrative Genomics & School of Mathematics and Statistics, The University of Melbourne, Melbourne, Victoria, Australia, ⁵Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom, ⁶DeepLife, Vernon, France, ⁷Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁸University of Newcastle, Newcastle, United Kingdom, ⁹Flinders Medical Centre, Adelaide, Australia, ¹⁰Newcastle University, Newcastle upon Tyne, United Kingdom
Background/Purpose: Many patients living with rheumatoid arthritis (RA) can achieve remission with modern treat-to-target disease-modifying anti-rheumatic drugs (DMARDs), albeit with the risks associated with long-term…
Abstract Number: 1648 • ACR Convergence 2025
Predicting Worse Disease Activity, QOL, and Progression to Advanced Therapies at 12 and 24 months in Early RA: Results from the Canadian Early Arthritis Cohort (CATCH)
Susan J. Bartlett¹, Marie-France Valois², Clifton Bingham³, Janet Pope⁴, Hugues Allard-Chamard⁵, Louis Bessette⁶, Gilles Boire⁷, Carol Hitchon⁸, Glen Hazlewood⁹, Bindee Kuriya¹⁰, Carter Thorne¹¹ and Vivian Bykerk¹², ¹McGill University, Beaconsfield, QC, Canada, ²McGill University, Pointe-Claire, QC, Canada, ³Johns Hopkins University, Baltimore, MD, ⁴University of Western Ontario, London, ON, Canada, ⁵Université de Sherbrooke, Sherbrooke, Canada, ⁶Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ⁷Retired, Sherbrooke, QC, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰University of Toronto - Toronto, Toronto, ON, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Hospital for Special Surgery, New York, NY
Background/Purpose: Pain, fatigue, and emotional distress are common in new RA patients. It is unclear whether co-occurring symptoms predict worse outcomes and progression to advanced therapies…
Abstract Number: 1364 • ACR Convergence 2025
Efficacy Of Ayurvedic Treatment Versus Placebo, Each In Combination With Methotrexate In Early RA Over 20 Weeks: An Exploratory Randomized Control Trial
Prativa Priyadarshani Sethi¹, Venkatesh Srinivasa Pai², Rajat Ranka², Avneet Kumar Gupta³, Ashish Baweja⁴, ritu sangwan⁵, Abhishek Rai⁶, Sryla Punjadath¹ and Nithya Maskani², ¹All India Institute of Medical Sciences, Rishikesh, Rishikesh, Uttarakhand, India, ²AIIMS RISHIKESH, Rishikesh, Uttarakhand, India, ³AIIMS RISHIKESH, Lucknow, Uttar Pradesh, India, ⁴Medanta, The Medicity, Gurugram, New Delhi, Delhi, India, ⁵AIIMS ,Rishikesh, Rishikesh, Uttarakhand, India, ⁶AIIMS ,RISHIKESH, Bhilai, Chhattisgarh, India
Background/Purpose: Early rheumatoid arthritis (RA) is a critical therapeutic window where prompt treatment targeting remission or low disease activity can significantly reduce long-term disability and…
Abstract Number: 1345 • ACR Convergence 2025
Upregulated TLR Signaling Identified in Difficult-to-Treat RA: A Propensity Score–Matched Transcriptome Study
YOSHINORI NISHIURA¹, YOSHIHARU SATO², YU NAKAI¹, MOE TOKUNAGA¹, KENTA SHIDAHARA¹ and YOSHINOBU KOYAMA³, ¹Japan Red Cross Okayama Hospital, Okayama-shi, Okayama, Japan, ²DNA Chip Research Inc., Kawasaki-shi, Kanagawa, Japan, ³Japanese Red Cross Okayama Hospital, Okayama, Okayama, Japan
Background/Purpose: Difficult-to-treat rheumatoid arthritis (D2T-RA) represents a clinically challenging RA subset defined by failure to achieve disease control despite multiple conventional and advanced therapies. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].